ArticleOncoTargets and therapy2017

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.

Shen-Cun Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.